Sermorelin 5mg

Additional Info

Properties

• Sermorelin Chemical Formula: C149H246N44O42S
• Sermorelin Molecular Weight: 3357.9 g/mol
• Sermorelin Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
• Total Amount of the Active Ingredient: 5mg (1 vial)
• Shelf Life: 36 months

Shipping

• USA
• Canada

Disclaimer

The information provided does not substitute medical advice, diagnosis, or treatment. For any medical concerns, consult your physician or a qualified healthcare provider promptly. Do not delay or disregard medical advice based on information you have read or seen. We assume no responsibility or liability for the use of our research compounds and products. Please note, these products are sold exclusively for research purposes and are not intended for personal use.

Additional Label & Product Information

Essential Warning:

• These chemicals are for research or laboratory use only and are not approved by the FDA for human consumption.

Usage Instructions:

• Avoid skin and eye contact. In case of contact, rinse thoroughly with water.
• Seek medical advice if feeling unwell or in case of accidental ingestion.
• Store the lyophilized (freeze-dried) peptide at room temperature upon receipt to maintain stability. Avoid frequent freeze-thaw cycles.

Product Disclaimer:

• This product is not intended to diagnose, treat, cure, or prevent any disease.
• Use only as directed by specific research or laboratory protocols.

Resources

1. Bagno LL, Kanashiro-Takeuchi RM, Suncion VY, et al. investigated how growth hormone-releasing hormone agonists can reduce myocardial infarct scar in swine suffering from subacute ischemic cardiomyopathy. Their findings were published in the Journal of the American Heart Association in 2015.
2. Kanashiro-Takeuchi RM, Szalontay L, Schally AV, et al. proposed a novel therapeutic approach for heart failure post-myocardial infarction by targeting the growth hormone-releasing hormone receptor. This study was featured in Oncotarget in 2015.
3. Tang S, Luo Z, Qiu X, et al. explored interactions between growth hormone-releasing hormone and GABAARs in the brains of epilepsy patients and animal models. Their research, published in Scientific Reports in 2017, sheds light on potential neurological implications.
4. Shepherd BS, Johnson JK, Silverstein JT, et al. examined the endocrine and orexigenic effects of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss). Their study, published in Comparative Biochemistry and Physiology Part A, illustrates hormonal responses in aquatic organisms.
5. Walker RF discussed Sermorelin as a promising management strategy for adult-onset growth hormone insufficiency in his article published in Clinical Interventions in Aging in 2006.
6. Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG. investigated partial tachyphylaxis to somatostatin analogues in a patient with acromegaly, highlighting receptor desensitization and circulating antibody roles. Their findings were published in the European Journal of Endocrinology in 2002.